Cannabinoid receptor type 2–5-hydroxytryptamine receptor 1A heteromer (CB2–5-HT1A)

The Cannabinoid receptor type 2–5-hydroxytryptamine receptor 1A (CB2–5-HT1A) heteromer is a functional macromolecular complex formed by the physical association of the CB2 cannabinoid receptor and the 5-HT1A serotonin receptor (Franco et al., 2019). This heteromer is primarily expressed in the central nervous system, where its levels are significantly upregulated under pathological conditions such as neonatal hypoxic-ischemic brain damage and neuroinflammation (Navarro et al., 2022). Functionally, the complex exhibits unique signaling properties, including cross-talk and cross-antagonism, where the pharmacological modulation of one receptor component directly influences the activity of the other. Phytocannabinoids like cannabidiol (CBD) interact with this heteromer to exert neuroprotective, anxiolytic, and antidepressant-like effects by modulating its formation and signaling pathways (Yang et al., 2024). Research indicates that CBD can revert the aberrant upregulation of these heteromers in hypoxic conditions, thereby protecting neurons from death (Navarro et al., 2022). Targeting the CB2–5-HT1A heteromer represents a promising therapeutic strategy for treating neonatal brain injury and psychiatric disorders like depression and anxiety (Yang et al., 2024). This approach potentially offers improved efficacy and a better safety profile by avoiding the psychoactive effects associated with CB1 receptor activation (Vasefi, 2025).

Other names

CB2-5HT1A-HetsCB2-5-HT1A heteroreceptor complexCB2-5-HT1A receptor complexCannabinoid CB2-Serotonin 5-HT1A heteromer

Modulation of the CB2–5-HT1A heteromer's unique signaling profile, including the stabilization of the receptor-receptor interaction by cannabidiol and the use of dual agonists to trigger synergistic neuroprotective and antidepressant pathways (Navarro et al., 2022; Yang et al., 2024).